# Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach

> **NCT02008721** · PHASE3 · COMPLETED · sponsor: **Dr. Johannes Levin** · enrollment: 92 (actual)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** EGCG as putative neuroprotective agent
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02008721
- **Lead sponsor:** Dr. Johannes Levin
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02008721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02008721, "Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02008721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*